LSBio

We’re excited to share LSBio is now part of Absolute Biotech, a new company that unites multiple life science brands into one organization specializing in antibody reagents and services. It is still very much business as usual for our customers and partners, but we’re excited for what the future holds. Learn more at absolutebiotech.com.

We’re excited to share Absolute Antibody and its sister company Kerafast have been acquired by the reagent company | LifeSpan BioSciences, Inc.! It is still very much business as usual for our customers and partners, and the acquisition will enable us to continue the rapid growth of our recombinant antibody catalog and services.

LSBio Acquires Absolute Antibody Ltd. LSBio (LSBio™), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolu

Dec 1st is World AIDS Day! The current COVID-19 pandemic has made it more difficult than ever for PLHIV (people living with HIV) to access testing and adequate treatment. The impact of the pandemic is particularly devastating to people living in resource-constrained settings, like sub-Saharan Africa, where its effects are compounded by high poverty rates, inadequately resourced health systems, and co-occurring HIV epidemics. Service disruptions for HIV testing and treatment can result in an increase in HIV-related deaths and onward transmission. The following article explores the impact of the COVID-19 pandemic on HIV testing for sexual partners of persons diagnosed HIV+ and Assisted Partner Notification Services (aSP), and outlines a large-scale aPS implementation project and HIV self-test (HIVST) distribution in Western Kenya: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265868/

October is Breast Cancer Awareness month! Breast cancer is the most common malignancy in women worldwide and the second leading cause of cancer deaths in women in the United States. Classification is based upon microscopic diagnosis and staining with immunohistochemistry (IHC) markers such as HER2 (ERBB2), Estrogen Receptor (ESR1), and Progesterone Receptor (PR). Markers are also used to determine if a cancer is invasive, to subtype ductal and lobular carcinomas, to demonstrate mammary origin for a breast cancer, study tumor proliferation or apoptosis, angiogenesis, immune reaction to the tumor, and to study genes upregulated in hereditary breast cancer.

For a list of our antibodies to critical breast cancer markers, visit: https://www.lsbio.com/research-areas/breast-cancer-ihc-markers.